Form 4: Adverum Biotechnologies CEO Acquires 315,000 Shares Through Stock Option Vesting

Adverum Biotechnologies CEO Laurent Fischer acquired 315,000 shares of common stock through the vesting of performance-based stock options.

Summary

• On October 3, 2023, Adverum Biotechnologies CEO Laurent Fischer acquired 315,000 shares of common stock due to the vesting of performance-based stock options.
• The vesting was triggered by the meeting of a performance condition related to the dosing of patients in the LUNA trial.
• The Compensation Committee certified that the Vesting Commencement Date occurred on August 16, 2023.
• The options vest monthly, with all shares becoming fully vested and exercisable by the second anniversary of the Vesting Commencement Date, contingent upon continued service.
• The exercise price of the stock option is $1.29.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The vesting of stock options indicates that performance targets have been met, which is a positive sign. However, it's a routine event and doesn't necessarily indicate a major shift in the company's prospects.

Positives

• The vesting of performance-based stock options suggests that the company has met certain performance criteria related to the LUNA trial.
• The CEO's continued service is required for the options to fully vest, aligning his interests with the company's long-term success.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting schedule implies continued focus on the LUNA trial and the CEO's continued service with the company.

Industry Context

This type of stock option vesting is a common practice in the biotechnology industry to incentivize and retain key executives, aligning their interests with the company's performance and long-term goals.

Comparison to Industry Standards

• Stock option grants and vesting schedules are standard compensation practices in the biotech industry.
• Companies like Regeneron, Amgen, and Biogen also use stock options as part of their executive compensation packages.
• The vesting terms, such as monthly vesting over two years contingent on continued service, are typical for performance-based options.

Stakeholder Impact

• Shareholders: The vesting of stock options could have a minor dilutive effect.
• Employees: The vesting of stock options for the CEO could be seen as a positive sign of company progress.

Key Dates